Vimian Group AB
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, education, and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and surgical and dental products to veterinary clinics and universities, including dentistry and companion animal orthopedics under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of VIMIAN-ST would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (2021) — listing | $5,728 0.8× | $8,324 0.8× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Popular scenarios with VIMIAN
For illustration only — not investment advice. Past performance is not indicative of future results.